Is BAX a Buy? BAX Stock Analysis & Fair Value (2026)
Our model currently rates BAX as a Sell.
Get the latest investment score, DCF valuation, and buy/sell/hold insights for BAX (BAX).
Stock Analysis & Score Explanation
- ✓Fundament Score Analysis
- ✓Fair Value Analysis
- ✓Industry Trend
Fair Value Analysis
Weighted Fair Value
$18.39
Based on Multiple Valuation Methods (Weighted Average)
Current Price
$19.70
Individual Valuation Methods:
DCF Model Assumptions:
Some important financial metrics are missing or unavailable. This may affect the accuracy of our analysis.
Stock Analysis & Score Explanation
This stock receives a score of 43.20/100 with a Sell recommendation. Financial health scored 25.41/55, competitive position 9.25/25, macro risk assessment 8.34/10, and risk-adjusted returns 0.2/10. The analysis considers current market conditions and fundamental metrics. This score reflects the financial health, growth potential, and overall valuation of the stock, helping investors determine whether it may be overvalued or undervalued. Learn more about the AInvestor Score and how it is calculated. See how we convert scores and fair-value signals into actionable labels in the AInvestor Recommendation glossary entry.
Overvalued by 6.67%. Our detailed stock valuation analysis indicates that overvalued at current market prices by 6.67%. The weighted fair value of $18.39 is calculated using multiple proven valuation methods, including Discounted Cash Flow (DCF), Peter Lynch Fair Value, Trading Multiples P/E, and Earnings Power Value (EPV). This comprehensive stock analysis is designed to guide informed investment decisions.
Industry Context: Healthcare
2026 Trend: 📈 Positive Outlook
Positive outlook supported by aging demographics driving secular growth, innovative drug approvals beyond GLP-1, and persistent pricing power. Despite regulatory risks and GLP-1 hype normalization, fundamental healthcare demand growth remains strong.
Bubble Watch: GLP-1 Hype Peak
GLP-1 drug manufacturers (Novo, Eli Lilly, Viking) trading at premium valuations on blockbuster expectations. Saturation, generic competition, and side effects could deflate valuations significantly.
Key 2026 Outlook Points
- →AI-driven drug discovery accelerates time-to-market, improving success rates
- →GLP-1 market matures with competing offerings and generics
- →Real-world outcomes data becomes reimbursement standard
- →Precision medicine and genetic therapies gaining mainstream adoption
Related Healthcare Stocks
Companies in the same sector